{"transactions":[{"id":724102,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:36:56.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000302/form4.xml","form_type":"4"}},{"id":974348,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.32,"underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974347,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.32,"underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974346,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":15.6,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974345,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974344,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":37,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974343,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":256.4,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974342,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":134.1,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974341,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":64.8,"underlying":"Common Stock","underlying_shares":4666},"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":974340,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T18:29:36.000Z","date":"2025-12-09","kind":"other","planned":false,"acquired":false,"shares":10333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001356950-25-000004","document":"form4-12102025_061232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000135695025000004/form4-12102025_061232.xml","form_type":"4"}},{"id":1101097,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:56.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000258","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000258/form4.xml","form_type":"4"}},{"id":1104901,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:26:09.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":10450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10450,"derivative":{"exercise_price":2.32,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001415889-25-017856","document":"form4-06202025_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000141588925017856/form4-06202025_080606.xml","form_type":"4"}},{"id":1467280,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:07:46.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000370/form4.xml","form_type":"4"}},{"id":1473019,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:44:59.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10520,"derivative":{"exercise_price":7.32,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001415889-24-017674","document":"form4-06202024_080655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000141588924017674/form4-06202024_080655.xml","form_type":"4"}},{"id":1612481,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:34:29.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":8823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on April 26, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":8823,"derivative":{"exercise_price":0.96,"expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":8823},"source":{"system":"sec-edgar","filing":"0001610717-24-000101","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000101/form4.xml","form_type":"4"}},{"id":1612480,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:34:29.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on April 26, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":29.1,"exercise_date":"2021-05-26","expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001610717-24-000101","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000101/form4.xml","form_type":"4"}},{"id":1651430,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T22:51:56.000Z","date":"2024-02-07","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.35,"value":135000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Shares of the Issuer's common stock were purchased in the Issuer's private placement of common stock pursuant to a Securities Purchase Agreement, dated February 5, 2024, by and among the Issuer and the other purchaser named therein. The shares of common stock acquired were purchased at a price per share of $1.35."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001415889-24-003209","document":"form4-02092024_100244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000141588924003209/form4-02092024_100244.xml","form_type":"4"}},{"id":1754332,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Warrant (Right to Buy)","published_at":"2023-10-27T20:13:06.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":91541,"price":0.125,"value":11442.625,"ownership":{"direct":true},"balance_after":91541,"derivative":{"exercise_price":0.7568,"exercise_date":"2023-10-25","expiration_date":"2030-10-25","underlying":"Common Stock","underlying_shares":91541},"source":{"system":"sec-edgar","filing":"0001610717-23-000318","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000318/form4.xml","form_type":"4"}},{"id":1754331,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-27T20:13:06.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":183083,"price":0.7568,"value":138557.2144,"ownership":{"direct":true},"balance_after":183083,"source":{"system":"sec-edgar","filing":"0001610717-23-000318","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000318/form4.xml","form_type":"4"}},{"id":1811889,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-09T20:33:20.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\"), became fully vested and exercisable (the \"Vested Option\").  Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":14.98,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001209191-23-045182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123045182/doc4.xml","form_type":"4"}},{"id":1811888,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-09T20:33:20.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\"), became fully vested and exercisable (the \"Vested Option\").  Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":13800},"source":{"system":"sec-edgar","filing":"0001209191-23-045182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123045182/doc4.xml","form_type":"4"}},{"id":1811887,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-09T20:33:20.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8261,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\"), became fully vested and exercisable (the \"Vested Option\").  Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":8261},"source":{"system":"sec-edgar","filing":"0001209191-23-045182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123045182/doc4.xml","form_type":"4"}},{"id":1811886,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-09T20:33:20.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12096,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\"), became fully vested and exercisable (the \"Vested Option\").  Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company's Stock Option (the \"Option\") vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":12096},"source":{"system":"sec-edgar","filing":"0001209191-23-045182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123045182/doc4.xml","form_type":"4"}},{"id":1811885,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-09T20:33:20.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25722,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\") entered into the Agreement and Plan of Merger (the \"Merger Agreement\"), with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the \"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased for $48.00 per share (the \"Offer Price\"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123045182/doc4.xml","form_type":"4"}},{"id":1811884,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-09T20:33:20.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15199,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\") entered into the Agreement and Plan of Merger (the \"Merger Agreement\"), with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the \"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased for $48.00 per share (the \"Offer Price\"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123045182/doc4.xml","form_type":"4"}},{"id":1816160,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T23:37:47.000Z","date":"2023-08-02","kind":"gift","planned":false,"acquired":false,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift to Harvard Law School for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":25722,"source":{"system":"sec-edgar","filing":"0001209191-23-044546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123044546/doc4.xml","form_type":"4"}},{"id":1816159,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T23:37:47.000Z","date":"2023-08-02","kind":"gift","planned":false,"acquired":false,"shares":220,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift to Gateway High School for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":27922,"source":{"system":"sec-edgar","filing":"0001209191-23-044546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123044546/doc4.xml","form_type":"4"}},{"id":1824890,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T20:11:17.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000212","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000212/form4.xml","form_type":"4"}},{"id":1826736,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T20:53:32.000Z","date":"2023-07-18","kind":"gift","planned":false,"acquired":false,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift to Boston Children's Hospital for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":28142,"source":{"system":"sec-edgar","filing":"0001209191-23-042750","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123042750/doc4.xml","form_type":"4"}},{"id":1830150,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-13T21:12:24.000Z","date":"2023-07-11","kind":"gift","planned":false,"acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift to Stanford University for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":30342,"source":{"system":"sec-edgar","filing":"0001209191-23-042235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123042235/doc4.xml","form_type":"4"}},{"id":1857111,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T21:17:37.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.56,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-036820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123036820/doc4.xml","form_type":"4"}},{"id":1908119,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-02T21:49:59.000Z","date":"2023-05-01","kind":"gift","planned":false,"acquired":true,"shares":6923,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":30642,"source":{"system":"sec-edgar","filing":"0001209191-23-026618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123026618/doc4.xml","form_type":"4"}},{"id":1908118,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-02T21:49:59.000Z","date":"2023-05-01","kind":"gift","planned":false,"acquired":false,"shares":6923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift for no consideration."}],"balance_after":15199,"source":{"system":"sec-edgar","filing":"0001209191-23-026618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123026618/doc4.xml","form_type":"4"}},{"id":1942847,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T20:47:36.000Z","date":"2023-03-17","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":29.05,"value":290500.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":23719,"source":{"system":"sec-edgar","filing":"0001209191-23-020299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123020299/doc4.xml","form_type":"4"}},{"id":1942846,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T20:47:36.000Z","date":"2022-10-24","kind":"gift","planned":false,"acquired":true,"shares":30719,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne E. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":33719,"source":{"system":"sec-edgar","filing":"0001209191-23-020299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123020299/doc4.xml","form_type":"4"}},{"id":1942845,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T20:47:36.000Z","date":"2022-10-24","kind":"gift","planned":false,"acquired":false,"shares":30719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person transferred as a bona fide gift for no consideration."}],"balance_after":22122,"source":{"system":"sec-edgar","filing":"0001209191-23-020299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919123020299/doc4.xml","form_type":"4"}},{"id":2221262,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:13:42.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.34,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013390","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013390/doc1.xml","form_type":"4"}},{"id":2232495,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-14T20:22:00.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.9903,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-036686","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919122036686/doc4.xml","form_type":"4"}},{"id":2238977,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-06-08T20:53:48.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier to occur of: (i) the one-year anniversary of the grant date and (ii) the subsequent annual meeting of the Registrant's stockholders, in each case, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":21250,"derivative":{"exercise_price":14.98,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001209191-22-035071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919122035071/doc4.xml","form_type":"4"}},{"id":2401404,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-11T22:33:21.000Z","date":"2021-12-30","kind":"gift","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person \ttransferred as a bona fide gift for no consideration, which shares have not been sold and remain subject to the lock-up agreement entered into in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by The James P. Scopa and Anne \t\tE. Kenner Family Trust, Anne E. Kenner and James P. Scopa, Trustees."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-22-008948","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919122008948/doc5.xml","form_type":"5"}},{"id":2401403,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-11T22:33:21.000Z","date":"2021-12-30","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock that the Reporting Person \ttransferred as a bona fide gift for no consideration, which shares have not been sold and remain subject to the lock-up agreement entered into in connection with the Issuer's initial public offering."}],"balance_after":52841,"source":{"system":"sec-edgar","filing":"0001209191-22-008948","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919122008948/doc5.xml","form_type":"5"}},{"id":2506880,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T21:38:00.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":50000,"price":2.18,"value":109000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $2.17 to $2.185. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held directly by James Paul Scopa and Anne Eunice Kenner, as Trustees of The James P. Scopa and Anne E. Kenner Family Trust."}],"balance_after":3334,"source":{"system":"sec-edgar","filing":"0001209191-21-065115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121065115/doc4.xml","form_type":"4"}},{"id":2567569,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-17T01:30:38.000Z","date":"2021-09-14","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":5600,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0001209191-21-056526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121056526/doc4.xml","form_type":"4"}},{"id":2567568,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-17T01:30:38.000Z","date":"2021-09-14","kind":"grant","acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":8200,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001209191-21-056526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121056526/doc4.xml","form_type":"4"}},{"id":2567567,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-17T01:30:38.000Z","date":"2021-09-14","kind":"grant","acquired":true,"shares":8261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":8261,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":8261},"source":{"system":"sec-edgar","filing":"0001209191-21-056526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121056526/doc4.xml","form_type":"4"}},{"id":2567566,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-17T01:30:38.000Z","date":"2021-09-14","kind":"grant","acquired":true,"shares":12096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":12096,"derivative":{"exercise_price":17,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":12096},"source":{"system":"sec-edgar","filing":"0001209191-21-056526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121056526/doc4.xml","form_type":"4"}},{"id":2567565,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T01:30:38.000Z","date":"2021-09-15","kind":"purchase","acquired":true,"shares":6000,"price":17,"value":102000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares of Common Stock reported in the Reporting Holder's Form 3 reflected the conversion of derivative securities based on the midpoint of the Issuer's initial public offering range of $16.00 per share. The number of shares of Common Stock reflected in this Form 4 reflects the adjusted number of shares issued based on the higher initial public offering price of $17.00 per share, and does not reflect a disposition of shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met."}],"balance_after":55841,"source":{"system":"sec-edgar","filing":"0001209191-21-056526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121056526/doc4.xml","form_type":"4"}},{"id":2712182,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-15T00:03:20.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.7,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-032958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919121032958/doc4.xml","form_type":"4"}},{"id":2738645,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-27T20:42:51.000Z","date":"2021-04-26","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from April 26, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":30000,"derivative":{"exercise_price":29.1,"expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-21-008646","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761921008646/doc1.xml","form_type":"4"}},{"id":3099682,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T21:47:22.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":30000,"derivative":{"exercise_price":25.64,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-038963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919120038963/doc4.xml","form_type":"4"}},{"id":3160932,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-05T22:44:19.000Z","date":"2020-05-04","kind":"exercise","acquired":false,"shares":23334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3 of the total number of shares subject to the option vest and become exercisable on each anniversary of May 1, 2019 (the \"Vesting Commencement Date\"), such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":46666,"derivative":{"exercise_price":6.48,"expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":23334},"source":{"system":"sec-edgar","filing":"0001209191-20-027287","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919120027287/doc4.xml","form_type":"4"}},{"id":3160931,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-05T22:44:19.000Z","date":"2020-05-04","kind":"exercise","acquired":true,"shares":23334,"price":6.48,"value":151204.32,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held directly by James Paul Scopa and Anne Eunice Kenner, as Trustees of The James P. Scopa and Anne E. Kenner Family Trust."}],"balance_after":53334,"source":{"system":"sec-edgar","filing":"0001209191-20-027287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919120027287/doc4.xml","form_type":"4"}},{"id":3270405,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-15T01:58:02.000Z","date":"2020-02-14","kind":"purchase","acquired":true,"shares":10000,"price":13.75,"value":137500.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held directly by James Paul Scopa and Anne Eunice Kenner, as Trustees of The James P. Scopa and Anne E. Kenner Family Trust."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-20-009848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919120009848/doc4.xml","form_type":"4"}},{"id":3435967,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-16T20:16:14.000Z","date":"2019-08-15","kind":"grant","acquired":true,"shares":33750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020.  The options were issued in connection with an amendment to the company's non-employee director compensation policy, such that the director's total annual option grants correspond to the amended policy."}],"balance_after":45000,"derivative":{"exercise_price":13.41,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":33750},"source":{"system":"sec-edgar","filing":"0001209191-19-046311","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919119046311/doc4.xml","form_type":"4"}},{"id":3449052,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T20:23:36.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020."}],"balance_after":11250,"derivative":{"exercise_price":13.41,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001209191-19-044249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919119044249/doc4.xml","form_type":"4"}},{"id":3537992,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-06T23:42:30.000Z","date":"2019-05-06","kind":"purchase","acquired":true,"shares":20000,"price":6.71,"value":134200.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held directly by James Paul Scopa and Anne Eunice Kenner, as Trustees of The James P. Scopa and Anne E. Kenner Family Trust."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-19-027832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919119027832/doc4.xml","form_type":"4"}},{"id":3539653,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-03T20:40:15.000Z","date":"2019-05-01","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the total number of shares subject to the option vest and become exercisable on each anniversary of May 1, 2019 (the \"Vesting Commencement Date\"), such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":70000,"derivative":{"exercise_price":6.48,"expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-19-027398","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919119027398/doc4.xml","form_type":"4"}},{"id":3883975,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T20:07:41.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":4.99,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-039399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919118039399/doc4.xml","form_type":"4"}},{"id":4272498,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-26T20:16:47.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":4.96,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-041832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356950/000120919117041832/doc4.xml","form_type":"4"}},{"id":4592640,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":182011,"kind":"organization","name":"MPM BioVentures IV LLC","position":1,"cik":"0001358312","reported_name":"MPM BioVentures IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":34836,"kind":"person","name":"Scopa James Paul","position":2,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182012,"kind":"organization","name":"MPM BioVentures IV GP LLC","position":3,"cik":"0001358311","reported_name":"MPM BioVentures IV GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182013,"kind":"organization","name":"MPM Bio IV NVS Strategic Fund LP","position":4,"cik":"0001423213","reported_name":"MPM Bio IV NVS Strategic Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182014,"kind":"person","name":"KAILIAN VAUGHN M","position":5,"cik":"0001180429","reported_name":"KAILIAN VAUGHN M","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":2482,"kind":"person","name":"Foley Todd","position":6,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}}],"security":"Common Stock","published_at":"2016-09-29T18:03:16.000Z","date":"2016-09-27","kind":"other","acquired":false,"shares":713849,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by MPM Bio IV NVS Strategic Fund, L.P. (\"MPM NVS\"), without consideration to its limited partners."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by MPM Bio IV NVS Strategic Fund, L.P. (\"MPM NVS\"), without consideration to its limited partners."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The shares are held by MPM NVS."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MPM BioVentures IV GP LLC (\"BV IV GP LLC\") and MPM BioVentures IV LLC (\"BV IV LLC\") are the direct and indirect general partners of MPM NVS.  Luke Evnin, Ansbert Gadicke, Todd Foley, Vaughn M. Kailian and James Paul Scopa are the members of BV IV LLC.  Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein."}],"balance_after":1427698,"source":{"system":"sec-edgar","filing":"0001209191-16-143183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180429/000120919116143183/doc4.xml","form_type":"4"}}]}